Search Results - "Mehta, P. D."

Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study by LOPEZ, O. L, KULLER, L. H, MEHTA, P. D, BECKER, J. T, GACH, H. M, SWEET, R. A, CHANG, Y. F, TRACY, R, DEKOSKY, S. T

“…To examine the association between incident Alzheimer disease (AD), and plasma A beta 1-40 and A beta 1-42 levels in normal and mild cognitive impairment (MCI)…”
Get full text

Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease by De LEON, M. J., MOSCONI, L., BLENNOW, K., DeSANTI, S., ZINKOWSKI, R., MEHTA, P. D., PRATICO, D., TSUI, W., LOUIS, L. A. SAINT, SOBANSKA, L., BRYS, M., LI, Y., RICH, K., RINNE, J., RUSINEK, H.

“…:  It is widely believed that the path to early and effective treatment for Alzheimer's disease (AD) requires the development of early diagnostic markers that…”
Get full text

MRI and CSF studies in the early diagnosis of Alzheimer's disease by De Leon, M. J., DeSanti, S., Zinkowski, R., Mehta, P. D., Pratico, D., Segal, S., Clark, C., Kerkman, D., DeBernardis, J., Li, J., Lair, L., Reisberg, B., Tsui, W., Rusinek, H.

“… The main goal of our studies has been to use MRI, FDG‐PET, and CSF biomarkers to identify in cognitively normal elderly (NL) subjects and in patients with…”
Get full text

Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF by HULSTAERT, F, BLENNOW, K, IQBAL, K, POTTEL, H, VANMECHELEN, E, VANDERSTICHELE, H, IVANOIU, A, SCHOONDERWALDT, H. C, RIEMENSCHNEIDER, M, DE DEYN, P. P, BANCHER, C, CRAS, P, WILTFANG, J, MEHTA, P. D

“…To evaluate CSF levels of beta-amyloid(1-42) (Abeta42) alone and in combination with CSF tau for distinguishing AD from other conditions. At 10 centers in…”
Get full text

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease by Verwey, N A, van der Flier, W M, Blennow, K, Clark, C, Sokolow, S, De Deyn, P P, Galasko, D, Hampel, H, Hartmann, T, Kapaki, E, Lannfelt, L, Mehta, P D, Parnetti, L, Petzold, A, Pirttila, T, Saleh, L, Skinningsrud, A, Swieten, J C V, Verbeek, M M, Wiltfang, J, Younkin, S, Scheltens, P, Blankenstein, M A

“…Different cerebrospinal fluid (CSF) amyloid-beta 1-42 (Abeta(1-42)), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but…”
Get more information

Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease by Mehta, P.D, Pirttila, T, Patrick, B.A, Barshatzky, M, Mehta, S.P

“…We quantitated amyloid β proteins 1–40 (Aβ40) and 1–42 (Aβ42), and α1- antichymotrypsin (ACT) in matched cerebrospinal fluid (CSF) and plasma of 50 patients…”
Get full text

Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease by KULSTAD, J. J, GREEN, P. S, CRAFT, S, COOK, D. G, WATSON, G. S, REGER, M. A, BAKER, L. D, PLYMATE, S. R, ASTHANA, S, RHOADS, K, MEHTA, P. D

“…Hyperinsulinemia and insulin resistance are risk factors for memory impairment and Alzheimer disease (AD). Insulin regulates levels of the amyloid beta-peptide…”
Get full text

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment by de Leon, M.J., DeSanti, S., Zinkowski, R., Mehta, P.D., Pratico, D., Segal, S., Rusinek, H., Li, J., Tsui, W., Saint Louis, L.A., Clark, C.M., Tarshish, C., Li, Y., Lair, L., Javier, E., Rich, K., Lesbre, P., Mosconi, L., Reisberg, B., Sadowski, M., DeBernadis, J.F., Kerkman, D.J., Hampel, H., Wahlund, L.-O., Davies, P.

“…The diagnosis of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) is limited because it is based on non-specific behavioral and…”
Get full text

Decreased cerebrospinal fluid amyloid beta (1–40) levels in frontotemporal lobar degeneration by Pijnenburg, Y A L, Schoonenboom, S N M, Mehta, P D, Mehta, S P, Mulder, C, Veerhuis, R, Blankenstein, M A, Scheltens, P

“…The role of amyloid metabolism in the pathophysiology of frontotemporal lobar degeneration (FTLD) has yet to be elucidated. We compared CSF levels of amyloid…”
Get full text

Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment by de Leon, M.J, Segal, S, Tarshish, C.Y, DeSanti, S, Zinkowski, R, Mehta, P.D, Convit, A, Caraos, C, Rusinek, H, Tsui, W, Saint Louis, L.A, DeBernardis, J, Kerkman, D, Qadri, F, Gary, A, Lesbre, P, Wisniewski, T, Poirier, J, Davies, P

“…Cross-sectional cerebrospinal fluid (CSF) levels of tau and amyloid (A) beta (β) are of diagnostic importance for Alzheimer's disease (AD) and mild cognitive…”
Get full text

Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease by Mayeux, Richard, Tang, Ming-Xin, Jacobs, Diane M., Manly, Jennifer, Bell, Karen, Merchant, Carol, Small, Scott A., Stern, Yaakov, Wisniewski, Henry M., Mehta, Pankaj D.

“…Mutations in the amyloid precursor protein and presenilin 1 and 2 genes result in elevated plasma levels of the amyloid β‐peptide species terminating at amino…”
Get full text

Protein markers for Alzheimer disease in the frontal cortex and cerebellum by VERDILE, G, GNJEC, A, LAREU, R, LIM, D, DHARMARAJAN, A, MARTINS, R. N, MIKLOSSY, J, FONTE, J, VEURINK, G, BATES, K, KAKULAS, B, MEHTA, P. D, MILWARD, E. A, TAN, N

“…To compare proteins related to Alzheimer disease (AD) in the frontal cortex and cerebellum of subjects with early-onset AD (EOAD) with or without presenilin 1…”
Get full text

Plasma Aβ40 and Aβ42 and Alzheimer's disease: Relation to age, mortality, and risk by MAYEUX, R, HONIG, L. S, TANG, M.-X, MANLY, J, STERN, Y, SCHUPF, N, MEHTA, P. D

Get full text

Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease by Tapiola, Tero, Pirttilä, Tuula, Mikkonen, Mia, Mehta, Pankaj D., Alafuzoff, Irina, Koivisto, Keijo, Soininen, Hilkka

“…Earlier studies have shown elevated levels of tau protein and decreased levels of amyloid β42 in cerebrospinal fluid (CSF) from patients with Alzheimer's…”
Get full text

Structure Factor and Phonon Dispersion in Liquid Pb–Li Eutectic by Khambholja, S. G., Abhishek, A., Mehta, D. P., Thakore, B. Y.

“…Lead–lithium alloy in its eutectic form, i.e., Pb 83 Li 17 is one of the most promising candidates for its application as liquid blanket in fusion reactor with…”
Get full text

Putting the Individual Back Into Individual Growth Curves by Mehta, Paras D, West, Stephen G

“…Scaling of time (age) in latent growth curve (LGC) models has important implications for studies of development. When participants begin a study at different…”
Get full text

Traumatic Brain Injury Increases β‐Amyloid Peptide 1‐42 in Cerebrospinal Fluid by Raby, Charlotte A., Morganti‐Kossmann, Maria C., Kossmann, Thomas, Stahel, Philip F., Watson, M. Desiree, Evans, Lori M., Mehta, Pankaj D., Spiegel, Katharyn, Kuo, Yu‐Min, Roher, Alex E., Emmerling, Mark R.

“…: The β‐amyloid peptides, Aβ1‐42 and Aβ1‐40, were quantified in ventricular CSF taken daily for up to 3 weeks from six individuals with severe traumatic brain…”
Get full text

Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster by Pirttilä, T., Haanpää, M., Mehta, P. D., Lehtimäki, T.

“…Objectives– There are three major isoforms of apolipoprotein E (apoE), namely apoE2, apoE3, and apoE4, that are products of three alleles (ε2,ε3,ε4) at a…”
Get full text

Increased plasma amyloid β protein 1–42 levels in Down syndrome by Mehta, Pankaj D, Dalton, Arthur J, Mehta, Sangita P, Kim, Kwang Soo, Sersen, Eugene A, Wisniewski, Henryk M

“…Amyloid β protein 1–40 (A β40) and A β42 levels were quantitated in plasma from 43 persons with Down syndrome (DS; 26–68 years of age), 43 age-matched normal…”
Get full text

Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls by Pirttilä, T, Kim, K S, Mehta, P D, Frey, H, Wisniewski, H M

“…Cerebrospinal fluid (CSF) soluble amyloid beta-protein (sA beta) concentrations from 69 patients with Alzheimer's disease (AD), 23 patients with vascular…”
Get more information